| FOR IMMEDIATE RELEASE: | Contact: Michael Baum |
| Nov. 3, 1997 | (301) 975-2763 |
| TN-6151 |
The Commerce Department’s National Institute of Standards and Technology has announced that it will renew a multiyear research award under the Advanced Technology Program to 3-Dimensional Pharmaceuticals Inc. (Exton, Pa.) to develop a combination of novel protein engineering and crystallization methods to acquire previously unavailable molecular structure data on an important class of proteins belived to play a role in cardiovascular disease, pain, schizophrenia and many other medical problems.
The NIST award renewal is for $496,069. The three-year project, begun in 1995, is projected to receive a total of approximately $1,998,000 in ATP funding, matched by approximately $1,671,000 in industry funding.
Advanced Technology Program awards are designed to help industry pursue risky, challenging technologies that have the potential for a big pay-off for the nation’s economy. ATP projects focus on enabling technologies that will create opportunities for new, world-class products, services and industrial processes, benefiting not just the ATP participants but other companies and industries--and ultimately consumers and taxpayers. The ATP’s cost-shared funding enables industry to pursue promising technologies that otherwise would be ignored or developed too slowly to compete in rapidly changing world markets.
Detailed information on this project, Crystallization and Structural Determination of G-Coupled Protein Receptors, is provided in the fact sheet.
Go back to NIST News Page